SARS-CoV-2 in Immunocompromised Individuals

Overview

Journal Immunity

Publisher Cell Press

Specialty Allergy & Immunology

Date 2022 Oct 1

PMID 36182669

Authors

Susan DeWolf

Justin C Laracy

Miguel-Angel Perales

Mini Kamboj

Marcel R M van den Brink

Santosha Vardhana

Affiliations

Soon will be listed here.

Abstract

Immunocompromised individuals and particularly those with hematologic malignancies are at increased risk for SARS-CoV-2-associated morbidity and mortality due to immunologic deficits that limit prevention, treatment, and clearance of the virus. Understanding the natural history of viral infections in people with impaired immunity due to underlying conditions, immunosuppressive therapy, or a combination thereof has emerged as a critical area of investigation during the COVID-19 pandemic. Studies focused on these individuals have provided key insights into aspects of innate and adaptive immunity underlying both the antiviral immune response and excess inflammation in the setting of COVID-19. This review presents what is known about distinct states of immunologic vulnerability to SARS-CoV-2 and how this information can be harnessed to improve prevention and treatment strategies for immunologically high-risk populations.

Citing Articles

Virus-Specific T-Cell Therapy for the Management of Viral Infections in the Immunocompromised.

Koukoulias K, Papayanni P, Leen A, Vasileiou S Transfus Med Hemother. 2025; 52(1):5-26.

PMID: 39944414 PMC: 11813280. DOI: 10.1159/000540961.

Prolonged SARS-CoV-2 Viremia in an Immunocompromised Patient.

Abdulrasak M, Hootak S J Med Cases. 2025; 16(1):6-10.

PMID: 39759167 PMC: 11699861. DOI: 10.14740/jmc5064.

Novel gene mutation causing primary combined immunodeficiency disease: A case report and literature review.

Cao F, Shi Y, Deng F, Yan Y Cent Eur J Immunol. 2024; 49(3):300-307.

PMID: 39720273 PMC: 11664801. DOI: 10.5114/ceji.2024.142340.

Effects of combined immunosuppressant and hepatitis B virus antiviral use on COVID-19 vaccination in recipients of living donor liver transplantation.

Lee R, Choi J, Lee E, Lee J, Kim J, Kang S PeerJ. 2024; 12:e18651.

PMID: 39655328 PMC: 11627077. DOI: 10.7717/peerj.18651.

The signature of SARS-CoV-2-related genes predicts the immune therapeutic response and prognosis in breast cancer.

Fu R, Chen Y, Zhao J, Xie X BMC Med Genomics. 2024; 17(1):260.

PMID: 39482662 PMC: 11526603. DOI: 10.1186/s12920-024-02032-0.

References

Perry C, Luttwak E, Balaban R, Shefer G, Morales M, Aharon A . Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021; 5(16):3053-3061. PMC: 8362658. DOI: 10.1182/bloodadvances.2021005094. View

Bordt E, Shook L, Atyeo C, Pullen K, De Guzman R, Meinsohn M . Maternal SARS-CoV-2 infection elicits sexually dimorphic placental immune responses. Sci Transl Med. 2021; 13(617):eabi7428. PMC: 8784281. DOI: 10.1126/scitranslmed.abi7428. View

van Vliet M, Harmsen H, de Bont E, Tissing W . The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog. 2010; 6(5):e1000879. PMC: 2877735. DOI: 10.1371/journal.ppat.1000879. View

Tsang K, Ho P, Ooi G, Yee W, Wang T, Chan-Yeung M . A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003; 348(20):1977-85. DOI: 10.1056/NEJMoa030666. View

Davis H, Assaf G, McCorkell L, Wei H, Low R, Reem Y . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021; 38:101019. PMC: 8280690. DOI: 10.1016/j.eclinm.2021.101019. View

Bruel T, Hadjadj J, Maes P, Planas D, Seve A, Staropoli I . Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med. 2022; 28(6):1297-1302. DOI: 10.1038/s41591-022-01792-5. View

Wang E, Mao T, Klein J, Dai Y, Huck J, Jaycox J . Diverse functional autoantibodies in patients with COVID-19. Nature. 2021; 595(7866):283-288. DOI: 10.1038/s41586-021-03631-y. View

Piechotta V, Mellinghoff S, Hirsch C, Brinkmann A, Iannizzi C, Kreuzberger N . Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review. Blood Cancer J. 2022; 12(5):86. PMC: 9152308. DOI: 10.1038/s41408-022-00684-8. View

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

10.

Carmen J, Shrivastava S, Lu Z, Anderson A, Morrison E, Sankhala R . SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses. NPJ Vaccines. 2021; 6(1):151. PMC: 8668928. DOI: 10.1038/s41541-021-00414-4. View

11.

Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart D . Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. N Engl J Med. 2020; 383(3):288-290. PMC: 7217555. DOI: 10.1056/NEJMc2013656. View

12.

Peluso M, Lu S, Tang A, Durstenfeld M, Ho H, Goldberg S . Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis. 2021; 224(11):1839-1848. PMC: 8643408. DOI: 10.1093/infdis/jiab490. View

13.

Greco R, Alexander T, Burman J, Papa N, de Vries-Bouwstra J, Farge D . Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. Bone Marrow Transplant. 2021; 56(7):1493-1508. PMC: 8143059. DOI: 10.1038/s41409-021-01326-6. View

14.

Sepulcri C, Dentone C, Mikulska M, Bruzzone B, Lai A, Fenoglio D . The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study. Open Forum Infect Dis. 2021; 8(11):ofab217. PMC: 8135455. DOI: 10.1093/ofid/ofab217. View

15.

Peleg Y, Kudose S, DAgati V, Siddall E, Ahmad S, Nickolas T . Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection. Kidney Int Rep. 2020; 5(6):940-945. PMC: 7186120. DOI: 10.1016/j.ekir.2020.04.017. View

16.

Vardhana S, Baldo L, Morice 2nd W, Wherry E . Understanding T cell responses to COVID-19 is essential for informing public health strategies. Sci Immunol. 2022; 7(71):eabo1303. PMC: 10344642. DOI: 10.1126/sciimmunol.abo1303. View

17.

Mahase E . Covid-19: What do we know about "long covid"?. BMJ. 2020; 370:m2815. DOI: 10.1136/bmj.m2815. View

18.

Hall V, Ferreira V, Wood H, Ierullo M, Majchrzak-Kita B, Manguiat K . Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat Immunol. 2022; 23(3):380-385. DOI: 10.1038/s41590-021-01126-6. View

19.

Harrington P, Doores K, Saha C, Saunders J, Child F, Dillon R . Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients. Cancer Cell. 2021; 39(11):1448-1449. PMC: 8506143. DOI: 10.1016/j.ccell.2021.10.002. View

20.

Yek C, Warner S, Wiltz J, Sun J, Adjei S, Mancera A . Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series - 465 Health Care Facilities, United States, December 2020-October 2021. MMWR Morb Mortal Wkly Rep. 2022; 71(1):19-25. PMC: 8735560. DOI: 10.15585/mmwr.mm7101a4. View